11th Apr 2023 11:09
(Alliance News) - Oxford Nanopore Technologies PLC on Tuesday noted a National Institutes of Health Center for Alzheimer's & Related Dementias publication which showed a nanopore-based sequencing protocol delivered "scaled, accurate data".
Based in Oxford, England, Oxford Nanopore specialises in DNA/RNA sequencing technology.
The company said that a team led by researchers at the NIH CARD, the University of California, Santa Cruz, and the National Cancer Institute were behind the development of a protocol for human sequencing, supported by Oxford Nanopore's PromethION 48 sequencing device.
The study showed that the latest R10.4.1 PromethION 48 flow cells, combined with the latest version of Oxford Nanopore's 'Q20+ chemistry', significantly improved indel calling.
Indel calling is a type of sequencing analysis aimed identifying genetic variants.
Oxford Nanopore also explained that the study showed a clearer picture of the whole genome relating to Alzheimer's and related dementias by using nanopore DNA sequencing.
This is a technology that monitors changes to an electrical current as nucelic acids are passed through a protein nanopore. The resulting signal is decoded to provide a DNA sequence.
The company also explained that the protocol makes large-scale DNA sequencing projects feasible due to the "lower cost and higher throughput" of PromethION 48, which is capable of sequencing over 4,900 genomes per year, delivering scalability for large projects.
Oxford Nanopore said it delivers the most complete and accurate genomic data, at scale by combining very high single-molecule accuracy with the ability to reach all parts of the genome and characterise types of genetic variation.
Chief Executive Officer Gordon Sanghera said: "We are delighted to see this latest work from the NIH CARD team, whose approach demonstrates breakthrough accuracy with Oxford Nanopore's newest Q20+ chemistry and the R10 nanopore, whilst using the same platform. This shows that Oxford Nanopore now delivers comprehensive and accurate genomic data, at scale. We congratulate all the fantastic scientists who have contributed a huge amount to this significant project.
Shares were down 1.7% at 212.78 pence each in London on Tuesday morning.
By Sabrina Penty; Alliance News reporter
Comments and questions to [email protected]
Copyright 2023 Alliance News Ltd. All Rights Reserved.
Related Shares:
Oxford Nano